{"success":true,"data":{"pressRelease":{"id":"76214","rtpr_id":"nGNXhnCbr","ticker":"4565","exchange":"TSE Tokyo","all_tickers":["4565"],"title":"Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases","author":"Globe Newswire","published_at":"2026-06-30T08:27:03.677Z","article_body":"* This marks the fourth R&D milestone achieved under the collaboration, and\nthe second in 2026, reflecting the steady progress of development under the\ncollaboration\n* Under the terms of the agreement, Nxera is eligible to receive up to US$1.2\nbillion in potential option, development and commercial milestones, in\naddition to tiered royalties based on sales\nTokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co.,\nLtd. (“Nxera” or “the Company”; TSE 4565) announces that it has\nreached a fourth R&D milestone under its multi-target discovery collaboration\nwith AbbVie focused on neurological diseases, resulting in a payment of US$10\nmillion to Nxera.\n\nNxera and AbbVie entered this multi-target collaboration in 2022 to leverage\nNxera’s NxWave™ platform to discover novel medicines targeting G\nprotein-coupled receptors (GPCRs) associated with neurological disease. This\ncurrent milestone relates to the identification of validated and\ndifferentiated ‘hit’ molecules against a neurology target.\n\nSince the collaboration began, Nxera has hit all four expected near-term R&D\nmilestones and received US$40 million in payments from AbbVie; the first\nmilestone was achieved in June 2024, the second milestone in September 2025,\nand the third milestone in April 2026. Under the agreement with AbbVie, Nxera\nis eligible to receive further potential option, development and commercial\nmilestones totalling up to US$1.2 billion, plus tiered royalties on global\nsales.\n\nChristopher Cargill, President and CEO of Nxera Pharma, commented: “The\nachievement of this fourth milestone represents an important step forward,\ndemonstrating that multiple programs under our drug discovery collaboration\nwith AbbVie are steadily delivering results. We have now achieved two\nmilestones in 2026, and we believe that progress across multiple targets under\nthis collaboration further supports the productivity and future value of the\npartnership. We remain committed to expanding the value of our pipeline by\ncreating novel therapeutic candidates that address significant unmet medical\nneeds in neurological diseases.”\n\n–END–\n\nAbout Nxera Pharma\nNxera Pharma is a technology powered biopharma company in pursuit of new\nspecialty medicines to improve the lives of patients with unmet needs in Japan\nand globally. The Company has built an agile, new-generation commercial\nbusiness in Japan to develop and commercialize innovative medicines, including\nseveral launched products, to address this high-value, large and growing\nmarket and those in the broader APAC region. In addition, the Company is\nadvancing an extensive pipeline internally and in partnership with leading\npharma and biotech companies, powered by its unique NxWave™ GPCR\nstructure-based drug discovery platform. Nxera Pharma operates at key\nlocations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel\n(Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock\nExchange (ticker: 4565).\n\nFor more information, please visit www.nxera.life \nLinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma\n\nEnquiries:\n\nNxera – Media and Investor Relations\nShinya Tsuzuki, VP, Head of Investor Relations\n+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life\n\nMEDiSTRAVA (for International Media)\nMark Swallow, Frazer Hall, Erica Hollingsworth\n+44 (0)203 928 6900 | Nxera@medistrava.com\n\nForward-looking statements\nThis press release contains forward-looking statements, including statements\nabout the discovery, development, and commercialization of products. Various\nrisks may cause Nxera Pharma Group’s actual results to differ materially\nfrom those expressed or implied by the forward looking statements, including:\nadverse results in clinical development programs; failure to obtain patent\nprotection for inventions; commercial limitations imposed by patents owned or\ncontrolled by third parties; dependence upon strategic alliance partners to\ndevelop and commercialize products and services; difficulties or delays in\nobtaining regulatory approvals to market products and services resulting from\ndevelopment efforts; the requirement for substantial funding to conduct\nresearch and development and to expand commercialization activities; and\nproduct initiatives by competitors. As a result of these factors, prospective\ninvestors are cautioned not to rely on any forward-looking statements. We\ndisclaim any intention or obligation to update or revise any forward-looking\nstatements, whether as a result of new information, future events or\notherwise.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5cc74d52-c86f-4e21-8684-3496281fee15)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXhnCbr","title":"Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases","author":"Globe Newswire","ticker":"4565","created":"2026-06-30T08:27:03.677Z","tickers":["4565"],"exchange":"TSE Tokyo","article_body":"* This marks the fourth R&D milestone achieved under the collaboration, and\nthe second in 2026, reflecting the steady progress of development under the\ncollaboration\n* Under the terms of the agreement, Nxera is eligible to receive up to US$1.2\nbillion in potential option, development and commercial milestones, in\naddition to tiered royalties based on sales\nTokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co.,\nLtd. (“Nxera” or “the Company”; TSE 4565) announces that it has\nreached a fourth R&D milestone under its multi-target discovery collaboration\nwith AbbVie focused on neurological diseases, resulting in a payment of US$10\nmillion to Nxera.\n\nNxera and AbbVie entered this multi-target collaboration in 2022 to leverage\nNxera’s NxWave™ platform to discover novel medicines targeting G\nprotein-coupled receptors (GPCRs) associated with neurological disease. This\ncurrent milestone relates to the identification of validated and\ndifferentiated ‘hit’ molecules against a neurology target.\n\nSince the collaboration began, Nxera has hit all four expected near-term R&D\nmilestones and received US$40 million in payments from AbbVie; the first\nmilestone was achieved in June 2024, the second milestone in September 2025,\nand the third milestone in April 2026. Under the agreement with AbbVie, Nxera\nis eligible to receive further potential option, development and commercial\nmilestones totalling up to US$1.2 billion, plus tiered royalties on global\nsales.\n\nChristopher Cargill, President and CEO of Nxera Pharma, commented: “The\nachievement of this fourth milestone represents an important step forward,\ndemonstrating that multiple programs under our drug discovery collaboration\nwith AbbVie are steadily delivering results. We have now achieved two\nmilestones in 2026, and we believe that progress across multiple targets under\nthis collaboration further supports the productivity and future value of the\npartnership. We remain committed to expanding the value of our pipeline by\ncreating novel therapeutic candidates that address significant unmet medical\nneeds in neurological diseases.”\n\n–END–\n\nAbout Nxera Pharma\nNxera Pharma is a technology powered biopharma company in pursuit of new\nspecialty medicines to improve the lives of patients with unmet needs in Japan\nand globally. The Company has built an agile, new-generation commercial\nbusiness in Japan to develop and commercialize innovative medicines, including\nseveral launched products, to address this high-value, large and growing\nmarket and those in the broader APAC region. In addition, the Company is\nadvancing an extensive pipeline internally and in partnership with leading\npharma and biotech companies, powered by its unique NxWave™ GPCR\nstructure-based drug discovery platform. Nxera Pharma operates at key\nlocations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel\n(Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock\nExchange (ticker: 4565).\n\nFor more information, please visit www.nxera.life \nLinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma\n\nEnquiries:\n\nNxera – Media and Investor Relations\nShinya Tsuzuki, VP, Head of Investor Relations\n+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life\n\nMEDiSTRAVA (for International Media)\nMark Swallow, Frazer Hall, Erica Hollingsworth\n+44 (0)203 928 6900 | Nxera@medistrava.com\n\nForward-looking statements\nThis press release contains forward-looking statements, including statements\nabout the discovery, development, and commercialization of products. Various\nrisks may cause Nxera Pharma Group’s actual results to differ materially\nfrom those expressed or implied by the forward looking statements, including:\nadverse results in clinical development programs; failure to obtain patent\nprotection for inventions; commercial limitations imposed by patents owned or\ncontrolled by third parties; dependence upon strategic alliance partners to\ndevelop and commercialize products and services; difficulties or delays in\nobtaining regulatory approvals to market products and services resulting from\ndevelopment efforts; the requirement for substantial funding to conduct\nresearch and development and to expand commercialization activities; and\nproduct initiatives by competitors. As a result of these factors, prospective\ninvestors are cautioned not to rely on any forward-looking statements. We\ndisclaim any intention or obligation to update or revise any forward-looking\nstatements, whether as a result of new information, future events or\notherwise.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5cc74d52-c86f-4e21-8684-3496281fee15)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-30T08:27:03.727383338Z","server_sent_at_ms":1782808023727},"received_at":"2026-06-30T08:27:03.778Z","source_url":null},"analysis":{"id":"65494","press_release_id":"76214","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Nxera Pharma achieved a fourth R&D milestone in its collaboration with AbbVie, triggering a $10 million payment related to the identification of validated hit molecules against a neurology target.\n\nThis marks the second milestone reached in 2026, bringing total payments received under the agreement to $40 million since the partnership began in 2022.\n\nThe company retains eligibility for up to $1.2 billion in potential future milestones and tiered royalties on global sales, supporting the continued development of its pipeline.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Nxera hits 4th AbbVie milestone ($10M), validating platform and path to $1.2B upside."},"keyFigures":{"dealValueUsd":1200000000,"customDimensions":{"current_milestone_payment_usd":10000000,"total_milestone_payments_received_usd":40000000}},"quotedText":"The achievement of this fourth milestone represents an important step forward, demonstrating that multiple programs under our drug discovery collaboration with AbbVie are steadily delivering results.","namedEntities":{"people":[{"name":"Christopher Cargill","role":"President and CEO"}],"products":["NxWave™ platform"],"companies":[{"name":"Nxera Pharma Co., Ltd.","ticker":"4565"},{"name":"AbbVie","relationship":"partner"}],"dollarAmounts":[{"amount":"US$10 million","context":"fourth R&D milestone payment from AbbVie"},{"amount":"US$40 million","context":"total milestone payments received from AbbVie to date"},{"amount":"US$1.2 billion","context":"potential option, development and commercial milestones"}]},"materialImpact":{"score":3,"reasoning":"Receipt of a $10 million milestone payment validates the NxWave platform and strengthens the balance sheet. The potential for up to $1.2 billion in future milestones and royalties indicates significant remaining option value in the partnership."},"tickerRelevance":{"others":[],"primary":"4565"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"operational_milestone","sectorWeight":"biotech"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Nxera Pharma achieved a fourth R&D milestone in its collaboration with AbbVie, triggering a $10 million payment related to the identification of validated hit molecules against a neurology target.\n\nThis marks the second milestone reached in 2026, bringing total payments received under the agreement to $40 million since the partnership began in 2022.\n\nThe company retains eligibility for up to $1.2 billion in potential future milestones and tiered royalties on global sales, supporting the continued development of its pipeline.","key_figures":{"dealValueUsd":1200000000,"customDimensions":{"current_milestone_payment_usd":10000000,"total_milestone_payments_received_usd":40000000}},"named_entities":{"people":[{"name":"Christopher Cargill","role":"President and CEO"}],"products":["NxWave™ platform"],"companies":[{"name":"Nxera Pharma Co., Ltd.","ticker":"4565"},{"name":"AbbVie","relationship":"partner"}],"dollarAmounts":[{"amount":"US$10 million","context":"fourth R&D milestone payment from AbbVie"},{"amount":"US$40 million","context":"total milestone payments received from AbbVie to date"},{"amount":"US$1.2 billion","context":"potential option, development and commercial milestones"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-30T08:31:01.298Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"operational_milestone","sectorWeight":"biotech"}},"durationMs":157066,"modelName":"george-droid-qwen-72b"}}